

Amendment to the Claims

In the claims:

In accordance with the provisions of 37 C.F.R. § 1.121(c), please amend the claims as follows:

E 14  
Claim 1-45. (Previously Canceled)

Claim <sup>45</sup>46. (Currently Amended): An immunological adjuvant composition useful for enhancing the immune response against an active agent, comprising:

Rule 126  
a first adjuvant consisting essentially of amorphous calcium phosphate particles; and  
a liquid component,

said ~~first~~ adjuvant composition formulated as an injectable paste having a solids content of greater than or equal to 40 wt%.

Claim <sup>46</sup>47. (Currently Amended): An immunological adjuvant composition useful for enhancing the immune response against an active agent, comprising:

a first adjuvant comprising amorphous or nanocrystalline calcium phosphate particles; ~~and~~  
a liquid component; and

an active agent selected from the group consisting of antigens, bacteria or viruses or fragments thereof, haptens, allergens and immunogens,

said ~~first~~ adjuvant composition formulated as an injectable paste having a solids content of greater than or equal to 40 wt%; ~~and an active agent selected from the group consisting of antigens, bacteria or viruses or fragments thereof, haptens, allergens and immunogens.~~

Claim <sup>47</sup>48. (Previously Added): The composition of claim <sup>45 46</sup>46 or 47, wherein said particles have a diameter between 0.1 nm and 900 nm.

Claim <sup>48</sup>49. (Previously Added): The composition of claim <sup>47</sup>48, wherein 25-100% by weight of said composition consists of said particles having a diameter between 0.1 nm and 900 nm.

Filed September 15, 1998

Claim <sup>49</sup>~~50~~. (Previously Added): The composition of claim <sup>45</sup>~~46~~ or <sup>46</sup>~~47~~ further comprising a second adjuvant.

Claim <sup>50</sup>~~51~~. (Previously Added): The composition of claim <sup>49</sup>~~50~~, wherein said second adjuvant is selected from the group consisting of muramyl dipeptide, aluminum hydroxide, aluminum phosphate, hydroxyapatite, Incomplete Freund's Adjuvant, and Complete Freund's Adjuvant.

Claim <sup>51</sup>~~52~~. (Previously Added): The composition of claim <sup>49</sup>~~50~~, wherein the first and second adjuvants are selected so as to elicit an immune response from targeted cells or cell types.

Claim <sup>52</sup>~~53~~. (Previously Added): The composition of claim <sup>49</sup>~~50~~, wherein the first and second adjuvants are selected so as to elicit an immune response from cells of the same type.

Claim <sup>53</sup>~~54~~. (Previously Added): The composition of claim <sup>49</sup>~~50~~, wherein the first and second adjuvants are selected so as to elicit an immune response from cells of different types.

Claim <sup>54</sup>~~55~~. (Previously Added): The composition of claim <sup>49</sup>~~50~~, further comprising an endogenous adjuvanticity enhancing means.

Claim <sup>55</sup>~~56~~. (Previously Added): The composition of claim <sup>46</sup>~~47~~ wherein the active agent comprises an antigen.

Claim <sup>56</sup>~~57~~. (Previously Added): The composition of claim <sup>46</sup>~~47~~ further comprising a cytokine.

Claim <sup>57</sup>~~58~~. (Previously Added): The composition of claim <sup>45</sup>~~46~~, wherein said cytokine is selected from the group consisting of IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, IL-13, G-CSF, IL-15, GM-CSF, OSM, LIF, IFN- $\gamma$ , IFN- $\alpha$ , IFN- $\beta$ , B7.1, B7.2, TNF- $\alpha$ , TNF- $\beta$ , LT- $\beta$ , CD40 ligand, Fas ligand, CD27 ligand, CD30 ligand, 4-1BBL, IL-8, MCP-1, MIP- $\alpha$ , MIP- $\beta$ , RANTES, TGF- $\beta$ , IL-1 $\alpha$ , IL-1 $\beta$ , IL-1 RA, IL-10, IL-12, and MIF.

Claim <sup>58</sup>~~59~~. (Previously Added): The composition of claim <sup>46</sup>~~47~~, wherein the nanocrystalline calcium phosphate comprises hydroxyapatite.

Claim <sup>59</sup>~~60~~. (Previously Added): A method for stimulating an immune response in a mammal, said method comprising:

E14  
Contd

administering to the mammal a composition comprising amorphous or nanocrystalline calcium phosphate particles and an active agent selected from the group consisting of antigens, bacteria or viruses or fragments thereof, haptens, allergens and immunogens, formulated as an injectable paste having a solids content of greater than or equal to 40 wt%.

60  
Claim 61. (Currently Amended): A method for increasing immunogenicity of an antigen in a mammal, said method comprising:

co-administering both an antigen and a composition comprising amorphous calcium phosphate formulated as a ~~hardenable~~ an injectable paste having a solids content of greater than or equal to 40 wt%.

---